Grifols (NASDAQ:GRFS) Downgraded by Wall Street Zen to Hold

Grifols (NASDAQ:GRFS) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.

GRFS has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. reduced their price objective on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. Four analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Grifols Stock Performance

Grifols stock opened at $8.59 on Friday. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. The firm’s 50 day moving average price is $9.18 and its two-hundred day moving average price is $9.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GRFS. Allworth Financial LP lifted its stake in shares of Grifols by 15.7% in the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 1,096 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Grifols by 2.4% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock worth $427,000 after buying an additional 1,114 shares during the last quarter. Cerity Partners LLC raised its holdings in Grifols by 6.3% during the fourth quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 1,131 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,212 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,584 shares during the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.